Exhibit 99.1 Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update - The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024 - First patient dosed in a Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer - $177.7 million in cash, cash equivalents and short-term investments expected to provide runway into t ...